SLC6A2 and major depressive disorder: In particular, arylpiperazines are aminergic G protein-coupled receptor (GPCR) ligands and neurotransmitter transporter inhibitors, making this group of compounds attractive in central nervous system (CNS) drug discovery for treating schizophrenia, depression, sleep disorders, and Parkinson’s disease (PD).